Scynexis (SCYX) Long-Term Investments (2016 - 2026)
Scynexis' (SCYX) quarterly Long-Term Investments came in at $17.0 million in Q2 2026, up 881.97% on a YoY basis from $1.7 million in Q2 2025, and up 29.61% quarter-over-quarter from $13.2 million in Q1 2026.
Analysis
Scynexis (SCYX) Long-Term Investments (2016 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Long-Term Investments for 5 consecutive years, with $17.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Long-Term Investments rose 881.97% year-over-year to $17.0 million; the trailing twelve-month figure through Jun 2026 stood at $17.0 million (up 881.97% YoY), and the FY2025 full-year result was $16.2 million, up 2.53% from the prior year.
- Long-Term Investments rose to $17.0 million in Q2 2026 per SCYX's latest filing, from $13.2 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $23.6 million in Q4 2023 and bottomed at $1.7 million in Q2 2025.
- Historically, Long-Term Investments has averaged $13.7 million across 4 years, with a median of $14.9 million in 2024.
- The sharpest annual moves came in 2025 and 2026: Long-Term Investments plunged 83.71% in 2025, then soared 881.97% in 2026.
- Over 4 years, Long-Term Investments stood at $23.6 million in 2023, then sank by 32.84% to $15.8 million in 2024, then advanced by 2.53% to $16.2 million in 2025, then climbed by 4.92% to $17.0 million in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $17.0 million, $13.2 million, and $16.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 5.79 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 9.83 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -4.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 1.77 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 17.05 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17.05 Mn |
| Mar 31, 2026 | 13.15 Mn |
| Dec 31, 2025 | 16.25 Mn |
| Jun 30, 2025 | 1.74 Mn |
| Mar 31, 2025 | 13.16 Mn |
| Dec 31, 2024 | 15.85 Mn |
| Sep 30, 2024 | 16.12 Mn |
| Jun 30, 2024 | 10.66 Mn |
| Mar 31, 2024 | 13.94 Mn |
| Dec 31, 2023 | 23.59 Mn |
| Sep 30, 2023 | 17.12 Mn |
| Jun 30, 2023 | 6.34 Mn |
| Sep 30, 2016 | 6.03 Mn |